AstraZeneca earnings Q2 2026 beat analyst expectations as core EPS hit $2.63 versus a $2.48 consensus, with oncology revenue ...
Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects ...
AstraZeneca Plc AZN on Monday posted mixed second-quarter 2026 results, beating Wall Street’s earnings estimates while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results